📄 Read our new white paper: ‘ The Case for Smarter GLP-1 Utilization: Cost, Coverage, and Clinical Outcomes '

AI driven
precision obesity medicine

We combine genomics, phenotypes, and advanced AI modeling to develop solutions that help clinicians choose the right intervention to optimize outcomes. MyPhenome^® Test is the first solution deployed by the platform to help enable a scalable shift toward systematic precision obesity care.

See the science Get in touch

0 people

are suffering from obesity worldwide.

The introduction of GLP-1s is transforming obesity care. But the variability in response complicates care, reduces compliance and increases costs.

Complex anti-obesity medication pipeline

68+

Mechanisms of action

161+

Obesity medications

Obesity care costs on the rise

Annual U.S. obesity costs

Annual U.S. direct healthcare cost

Projected 2033 spend on GLP-1 drugs

Advances in data analytics and access to unique patient data has allowed for novel approaches in understanding precision approaches to complex diseases such as obesity.

We believe the first use of these new techniques will be to enable precision obesity medicine to guide better treatment and lower costs; and that navigating the future of obesity medicine will depend on our platform-enabled novel approaches.

AI platform for precision medicine

Our AI-enabled platform integrates complex disease traits with genetic, clinical, and biomarker datasets to map the underlying biological pathways driving weight gain and treatment response. By translating these complexities into actionable insights, the platform enables a scalable shift toward systematic precision obesity care and empowers the delivery of the right intervention to the right patient, at the right time.

Platform in action: MyPhenome Test

By analyzing traits that influence appetite and energy balance, MyPhenome^® Test identifies a patient’s root-cause (phenotype), and informs which therapeutic pathway will work best based on peer-reviewed clinical studies. Through ongoing research and real-world deployments, the platform continues to demonstrate its ability to stratify patients, predict therapeutic pathways, and support more effective, scalable outcomes across the continuum of care.

Get in touch

Backed by the top leaders in obesity innovation

"This approach does what trial-and-error cannot by uncovering the root causes of obesity"
‍
- Dr. Andres Acosta, MD, PhD
‍

"[Phenomix's] dedication to advancing precision obesity medicine provides our members with important insights into the evolving landscape of patient care"
‍
- Mark Agcaoili

"The future of obesity medicine is precision medicine and Phenomix is the one leading this transformation."
‍
- Larry Cohen, PhD

References

Milken Institute, ScienceDaily . Economic impact of excess weight now exceeds $1.7 trillion: Costs include $1.24 trillion in lost productivity, according to study documenting role of obesity and overweight in chronic diseases, 2018. Available: https://www.sciencedaily.com/releases/2018/10/181030163458.htm

AI drivenprecision obesity medicine